Community/Retail

New evidence affirms hepatitis B birth-dose safety as the CDC makes it optional.

FDA-approved elinzanetant offers stronger nonhormonal relief for menopausal vasomotor symptoms, with promising trial results and simpler liver monitoring.

VOYAGE trial data show dupilumab improves pediatric asthma control and lowers exacerbations versus placebo, with higher remission and lung function gains earlier.

Wildfire smoke exposure increases asthma morbidity, underscoring the pharmacist’s role in medication preparedness and patient education.

Phase 2 trial data support the safety and efficacy of remibrutinib in adults with peanut allergy.

Emerging skin lipid biomarkers precede atopic dermatitis and food allergy, emphasizing barrier restoration as a key therapeutic target for pharmacists.

Michael Snyder, MD, of FuturHealth breaks down the patient safety risks of compounded glucagon-like peptide-1 (GLP-1) products and why structured care is essential as demand for these medications continues to surge.

WHO’s 2025 pregnancy diabetes guidance explains glucose monitoring, hemoglobin A1C targets, and metformin/insulin choices, with a focus on low-resource care.

Remibrutinib is the first oral advanced therapy for adults with chronic spontaneous urticaria (CSU) who remain uncontrolled on high-dose second-generation antihistamines.

Data show the peanut allergy sublingual immunotherapy (SLIT) tablet is well-tolerated across ages, offering promising sublingual immunotherapy desensitization with manageable adverse effects.

AAAAI 2026 highlights STMC-103H live biotherapeutic, showing reduced atopic disease risk in at-risk infants—potentially an early microbiome intervention for atopic dermatitis and food allergy.

A practical look at redesigning tasks and integrating artificial intelligence to improve efficiency and patient outcomes

Add beans and legumes to your diet for better health: Boost fiber and key nutrients while improving blood glucose, heart health, digestion, and weight control.

Careful history, adherence support, and proper medication technique are central to diagnosing and managing chronic cough in children.

Social determinants of health and environmental exposures during extreme weather events worsen asthma outcomes.

Remibrutinib, an oral Bruton tyrosine kinase inhibitor for chronic spontaneous urticaria (CSU), delivers itch and hive relief within 12 hours and sustains improvements through week 1.

Data presented at AAAAI 2026 show tapinarof cream improves sleep for children as young as 2 years with atopic dermatitis, easing nighttime disruption.

Sheryl L. Chow, PharmD, outlines the pharmacist's evolving role in cardiovascular prevention, heart failure management, and medication adherence during American Heart Month and beyond.

Thrifty White’s experiences provide practical lessons from designing, training, and standardizing a full-system model.

Explore PREVENT Risk Equations reshaping hypertension care, HFpEF therapy, and CKD-related hyperkalemia.

Learn how COVID-19 drives heart and vascular risks, why vaccines and antivirals help, and how pharmacists manage dangerous drug interactions.

Orforglipron, an oral GLP-1 medication, demonstrated superior weight loss and blood glucose control compared with oral semaglutide in patients with type 2 diabetes (T2D).

Awareness of the nonlinear response helps ensure patients are treated with the least intensive regimen that achieves meaningful control while minimizing harm and improving long-term therapeutic success.

The oral solution improves central diabetes insipidus dosing precision, helping pharmacy teams tailor therapy, counsel patients, and monitor hyponatremia.

Collaborative practice agreements expand pharmacists’ clinical authority and patient access.

Flexibility, priorities, and structure are just as important as your account balance.

Comprehensive prevention and cardiometabolic risk control in prediabetes can reduce long-term complications, improve survival, and lower health system burden.